William Blair Investment Management LLC Acquires 227,038 Shares of Krystal Biotech, Inc. $KRYS

William Blair Investment Management LLC boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 152.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 376,340 shares of the company’s stock after purchasing an additional 227,038 shares during the quarter. William Blair Investment Management LLC’s holdings in Krystal Biotech were worth $92,783,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Perigon Wealth Management LLC increased its holdings in Krystal Biotech by 0.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after purchasing an additional 41 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in Krystal Biotech by 2.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock worth $524,000 after purchasing an additional 55 shares in the last quarter. Sound View Wealth Advisors Group LLC increased its holdings in Krystal Biotech by 2.9% in the third quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock worth $354,000 after purchasing an additional 56 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Krystal Biotech by 1.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,896 shares of the company’s stock worth $1,454,000 after purchasing an additional 57 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Krystal Biotech by 1.2% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 5,086 shares of the company’s stock worth $1,254,000 after purchasing an additional 61 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Daniel Janney sold 11,803 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $275.59, for a total transaction of $3,252,788.77. Following the completion of the sale, the director owned 73,293 shares in the company, valued at approximately $20,198,817.87. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the sale, the insider owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This trade represents a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 97,714 shares of company stock worth $26,183,109. 13.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Citigroup upped their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Wall Street Zen raised Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $324.11.

Krystal Biotech Stock Down 1.6%

Shares of NASDAQ:KRYS opened at $299.45 on Friday. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $319.48. The stock’s 50 day moving average is $272.14 and its 200-day moving average is $257.06. The firm has a market capitalization of $8.83 billion, a price-to-earnings ratio of 40.03 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 7.98 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.